Stocks to Watch: Intel, Deckers, Edwards Lifesciences, Genmab
Intel reported Q2 results above Wall Street expectations and raised its 2026 capital expenditures outlook. Deckers Outdoor lifted its profit outlook and reported higher Q1 sales. Edwards Lifesciences posted double-digit Q2 revenue growth and raised the low end of guidance. Genmab and AbbVie’s lymphoma drug missed a Phase 3 primary endpoint.
How this was made
The 30-second read
Why it matters
The newest actionable facts are: INTC raised 2026 capex after beating Q2 expectations; DECK lifted profit outlook and reported higher Q1 sales but shares fell after-hours; EW grew revenues and lifted the bottom end of guidance; GMAB’s Phase 3 lymphoma drug failed its primary endpoint, pressuring its ADR.
Market read
Traders can use the guidance/capex changes and the Phase 3 failure as near-term catalysts for positioning, hedging, and volatility expectations into the next trading session.
What to watch
For INTC and DECK, the text does not include capex/profit outlook magnitude or margin commentary; for GMAB, the article does not state whether there are secondary endpoints, subgroup signals, or plans for follow-up studies.
Background
This is a multi-name “Stocks to Watch” wrap summarizing earnings/guidance updates for Intel, Deckers, and Edwards Lifesciences, plus a Phase 3 clinical outcome for Genmab.
Ticker impact
Intel reported Q2 results that beat expectations and raised its 2026 capex outlook, driving a post-bell rally.
Likely supports continued upside bias versus pre-print expectations, though follow-through depends on guidance details not provided here.
The article cites both an earnings beat and a specific outlook change (2026 capex), which are typically actionable for valuation and estimates.
Deckers lifted its profit outlook and reported higher Q1 sales, but the stock still fell in after-hours trading.
Near-term volatility likely, with direction dependent on whether the raised outlook offsets margin or demand worries.
The article provides both the positive operational updates and the negative after-hours price move, indicating a contested market interpretation.
Edwards Lifesciences posted double-digit Q2 revenue growth and lifted the bottom end of guidance, sending shares higher after the bell.
Supports further upside or reduced downside risk as traders reprice the lower end of guidance.
A guidance adjustment plus a growth datapoint is a direct catalyst, even though the article lacks the exact guidance numbers.
Genmab’s lymphoma drug co-developed with AbbVie failed a Phase 3 primary endpoint, and its ADR fell after the news.
Likely continued downside pressure as investors reassess probability-weighted pipeline cash flows.
A failed primary endpoint in Phase 3 is typically decisive for development prospects and is directly tied to the stock move cited.
Market effects
Signals ongoing bifurcation in healthcare and consumer discretionary: device makers can benefit from guidance trims upward, while oncology pipeline setbacks can quickly reprice risk.
Primarily US-listed price action (after-hours moves) with spillover to global healthcare sentiment via GMAB’s ADR.
Clinical-trial outcome (GMAB) can affect broader biotech risk appetite and read-across to oncology development programs.
Counterpoint
After-hours moves can reverse if investors already priced the headline; the article omits key details like margin, segment trends, and the exact guidance figures.
Key entities
- companyIntel
Raised 2026 capital expenditures outlook after Q2 results beat expectations.
- companyDeckers Outdoor
Lifted profit outlook and reported higher Q1 sales, yet shares fell after-hours.
- companyEdwards Lifesciences
Reported double-digit Q2 revenue growth and lifted the bottom end of guidance.
- companyGenmab
Phase 3 lymphoma drug failed primary endpoint; ADR fell.
